Tirzepatide Linked to Acute Liver Injury in Young Adult Patient
Background
Tirzepatide is a widely used dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, primarily prescribed for managing type 2 diabetes mellitus and obesity. While common gastrointestinal side effects are well-documented, hepatotoxicity (liver damage) is not a recognized complication. This study addresses the knowledge gap by presenting a case of drug-induced liver injury (DILI) potentially caused by tirzepatide.
Results
The patient exhibited clear signs of acute hepatocellular injury, which manifested within four weeks of starting tirzepatide. Crucially, after the cessation of tirzepatide, the patient demonstrated significant clinical improvement and complete biochemical recovery of liver function. This recovery was observed over the subsequent four weeks, strongly suggesting a direct causal link between the drug and the liver damage. The complete resolution of liver injury following tirzepatide withdrawal, coupled with the exclusion of all other potential causes, provides compelling evidence for tirzepatide-induced liver damage in this patient. The rapid onset of injury and subsequent rapid recovery upon drug discontinuation are key indicators supporting a diagnosis of Drug-Induced Liver Injury (DILI), adding to emerging reports of this rare adverse event.
Why It Matters
This case report is significant as it contributes to the emerging understanding of tirzepatide's potential adverse effects, specifically hepatotoxicity. The finding highlights the importance for clinicians to consider tirzepatide as a possible cause in patients presenting with unexplained liver injury, especially within the initial weeks of treatment. Early recognition of such rare but serious side effects is crucial for patient safety and could lead to updated prescribing guidelines or monitoring recommendations. Further research, including larger observational studies or pharmacovigilance data analysis, is warranted to better characterize the incidence and risk factors for tirzepatide-associated DILI.